1,137 research outputs found

    Dialogic speech as a field of compound-complex sentence communicative types application

    Get PDF
    The purpose of the article is to identify the specifics of compound-complex sentences functioning in the dialogues of script texts. The research work has a complex system to analyze the linguistic processes, which are manifested in script texts of British and American scriptwriter

    Reactions of 2-(5-methyl-2-phenyl-2H-1,2,3-diazaphosphol-4-yl)- 4H-1,3,2-benzodioxaphosphinin-4-one with chloral and hexafluoroacetone

    Get PDF
    Reaction of 2-(5-methyl-2-phenyl-2H-1,2,3-diazaphosphol-4-yl)-4H-1,3,2- benzodioxaphosphinin-4-one with chloral occurs at Piii atom of the 1,3,2-dioxaphosphinine cycle giving mostly 2-chlorocarbonylphenyl 2,2-dichlorovinyl (5-methyl-2-phenyl-2H-1,2,3-diazaphosphol-4-yl)phosphonate, whereas hexafluoroacetone incorporates into the 1,3,2-dioxaphosphorine cycle affording the corresponding 1,3,2-benzodioxaphosphepine. Β© 2011 Mendeleev Communications. All rights reserved

    Caged phosphorane with P-C bond based on chloral and 4,5-dimethyl-2-(2-oxo-1,2-diphenylethoxy)-1,3,2-dioxaphospholane

    Get PDF
    Β© 2015 Pleiades Publishing, Ltd. The key methods of caged phosphoranes synthesis are analyzed. Reaction of 4,5-dimethyl-2-(2-oxo-1,2-diphenylethoxy)-1,3,2-dioxaphospholane (prepared from the meso-form of 2,3-butanediol) with chloral has yielded the caged phosphorane containing a phosphorus-carbon bond: 1,1-(1,2-dimethylethylenedioxy)-3,4-diphenyl-6-trichloromethyl-2,5,7,1-trioxaphosphabicyclo[2.2.11,4]heptane; spatial structure of the product has been elucidated with X-ray diffraction analysis

    Retention of a six-membered ring in the reaction of 2-dialkylaminobenzo[e]- 1,3,2-dioxaphosphinin-4-ones with Pentafluorobenzaldehyde: O,N-exchange at phosphorus

    Get PDF
    The title reaction leads to the formation of diastereoisomeric 2-[(dialkylamino)(pentafluorophenyl)methyl]benzo[e]-1,3,2-dioxaphosphinine-2, 4-diones in a ratio of 70: 30. The configuration of chiral centres for the preferable diastereoisomer was determined by single crystal X-ray diffraction analysis. Β© 2013 Mendeleev Communications. All rights reserved

    ΠΠ½Ρ‚ΠΈΠΎΠΊΠΈΡΠ»ΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ тСрапия хроничСской обструктивной Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ… Π² условиях ΠšΡ€Π°ΠΉΠ½Π΅Π³ΠΎ Π‘Π΅Π²Π΅Ρ€Π°

    Get PDF
    The aim of this study was to investigate human antioxidant defense at various COPD stages and to substantiate administration of vitamins C and E as a part of complex treatment of COPD at the Far North. We followed-up 92 COPD patients aged 20 to 50 yrs (of them, 42 males). The control group consisted of 58 healthy persons of 20 to 45 yrs of age. A total blood antioxidant activity (TAA) was detected using G.I.Klebanov's method. Superoxide dismutase (SOD) and catalase levels in erythrocyte membrane were assessed with chemiluminescent methods. Lipid peroxide (LPO) activity was measured by malone dialdehyde (MDA) plasma concentration. We also investigated hepatic and renal functions, protein, lipoid, and carbohydrate metabolism. Patients with exacerbation of stage II COPD had increased LPO activity (2.97 Β± 0.12 nmol/ml compared to 1.86 Β± 0.09 nmol/ml in stable phase and 1.36 Β± 0.06 nmol/ml in controls) with TAA increased by 40 %. The stage III COPD patients demonstrated more significant growth of LPO activity (2.04 Β± 0.08 nmol/ml in stable phase and 3.44 Β± 0.15 nmol/ml in exacerbation; p < 0.05) accompanied by less prominent increase in TAA. Early stages of COPD were characterized by increased levels of antioxidant enzymes (2.44 Β± 0.06 ΞΌg/g of Hb for SOD and 8.30 Β± 0.15 –g/g of Hb for catalase compared to 1.56 Β± 0.02 and 7.36 Β± 0.10 ΞΌg/g Hb in controls). At the later COPD stages, the SOD level was less high and catalase concentration even decreased. COPD patients had increased concentrations of oxyproline (1.76 Β± 0.48 g/ml to 2.80 Β± 0.50 ΞΌg/ml; Ρ€<0.05 for both when compared to the controls) and Ξ±1-antitripsin (for stage II COPD, 284 Β± 47 ΞΌg/ml in stable phase and 240 Β± 20 ΞΌg/ml in exacerbation, for stage III COPD, 245 Β± 18 ΞΌg/ml and 223 Β± 15 ΞΌg/ml, respectively). Administration of vitamins C and E 25 mg/kg and 5 mg/kg of body weight, respectively, as a part of a complex therapy of the disease exacerbation resulted in shortening of exacerbation, improvement in clinical status and lung function, TAA activation, and lowering of LPO activity. Therefore, COPD is accompanied by significant activation of oxidantive processes, which depend on the stage and phase of the disease. The results allow including antioxidant vitamins in programs of treatment of COPD to be recommended.ЦСлью Ρ€Π°Π±ΠΎΡ‚Ρ‹ Π±Ρ‹Π»ΠΎ ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ состояния Π°Π½Ρ‚ΠΈΠΎΠΊΠΈΡΠ»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Π·Π°Ρ‰ΠΈΡ‚Ρ‹ ΠΎΡ€Π³Π°Π½ΠΈΠ·ΠΌΠ° Π½Π° Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… стадиях хроничСской обструктивной Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ… (Π₯ΠžΠ‘Π›) ΠΈ патогСнСтичСскоС обоснованиС примСнСния Π²ΠΈΡ‚Π°ΠΌΠΈΠ½ΠΎΠ² Π‘ ΠΈ Π• Π² комплСксной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π² условиях ΠšΡ€Π°ΠΉΠ½Π΅Π³ΠΎ Π‘Π΅Π²Π΅Ρ€Π°. Под наблюдСниСм Π½Π°Ρ…ΠΎΠ΄ΠΈΠ»ΠΈΡΡŒ 92 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π₯ΠžΠ‘Π› Π² возрастС ΠΎΡ‚ 20 Π΄ΠΎ 50 Π»Π΅Ρ‚ (42 ΠΌΡƒΠΆΡ‡ΠΈΠ½Ρ‹ ΠΈ 50 ΠΆΠ΅Π½Ρ‰ΠΈΠ½). ΠšΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŒΠ½ΡƒΡŽ Π³Ρ€ΡƒΠΏΠΏΡƒ составили 58 практичСски Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π»ΠΈΡ† Π² возрастС ΠΎΡ‚ 20 Π΄ΠΎ 45 Π»Π΅Ρ‚. ΠžΠ±Ρ‰ΡƒΡŽ Π°Π½Ρ‚ΠΈΠΎΠΊΡΠΈΠ΄Π°Π½Ρ‚Π½ΡƒΡŽ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ (АОА) ΠΊΡ€ΠΎΠ²ΠΈ опрСдСляли ΠΏΠΎ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρƒ Π“.И.КлСбанова ΠΈ Π΄Ρ€. Π‘ΠΎΠ΄Π΅Ρ€ΠΆΠ°Π½ΠΈΠ΅ супСроксиддисмутазы (Π‘ΠžΠ”) ΠΈ ΠΊΠ°Ρ‚Π°Π»Π°Π·Ρ‹ Π² ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π°Ρ… эритроцитов выявляли Ρ…Π΅ΠΌΠΈΠ»ΡŽΠΌΠΈΠ½Π΅ΡΡ†Π΅Π½Ρ‚Π½Ρ‹ΠΌΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ. Π˜Π½Ρ‚Π΅Π½ΡΠΈΠ²Π½ΠΎΡΡ‚ΡŒ пСрСкисного окислСния Π»ΠΈΠΏΠΈΠ΄ΠΎΠ² (ΠŸΠžΠ›) ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»Π°ΡΡŒ ΠΏΠΎ ΡΠΎΠ΄Π΅Ρ€ΠΆΠ°Π½ΠΈΡŽ Π² ΠΊΡ€ΠΎΠ²ΠΈ ΠΌΠ°Π»ΠΎΠ½ΠΎΠ²ΠΎΠ³ΠΎ диальдСгида (ΠœΠ”Π). Π’Π°ΠΊΠΆΠ΅ исслСдовали биохимичСскиС ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ ΠΏΠ΅Ρ‡Π΅Π½ΠΈ ΠΈ ΠΏΠΎΡ‡Π΅ΠΊ, Π±Π΅Π»ΠΊΠΎΠ²ΠΎΠ³ΠΎ, Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΈ ΡƒΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°. Π£ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… с обострСниСм Π₯ΠžΠ‘Π› 2-ΠΉ стадии ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ интСнсивности ΠŸΠžΠ› (2,97 Β± 0,12 нмоль/ΠΌΠ» ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с 1,86 Β± 0,09 нмоль/ΠΌΠ» Π² Ρ„Π°Π·Π΅ рСмиссии ΠΈ 1,36 Β± 0,06 нмоль/ΠΌΠ» Ρƒ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ…) ΡΠΎΡ‡Π΅Ρ‚Π°Π»ΠΎΡΡŒ с ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ΠΌ АОА ΠΊΡ€ΠΎΠ²ΠΈ Π½Π° 40 %. Π£ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… с Π₯ΠžΠ‘Π› 3-ΠΉ стадии Π±ΠΎΠ»Π΅Π΅ Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΠ΅ ΡƒΠ²Π΅Π»ΠΈΡ‡Π΅Π½ΠΈΠ΅ интСнсивности ΠŸΠžΠ› (2,04 Β± 0,08 нмоль/ΠΌΠ» Π² Ρ„Π°Π·Π΅ рСмиссии ΠΈ 3,44 Β± 0,15 нмоль/ΠΌΠ» ΠΏΡ€ΠΈ обострСнии; p < 0,05) ΡΠΎΡ‡Π΅Ρ‚Π°Π»ΠΎΡΡŒ с мСньшим нарастаниСм ΠΎΠ±Ρ‰Π΅ΠΉ АОА ΠΊΡ€ΠΎΠ²ΠΈ. На Ρ€Π°Π½Π½ΠΈΡ… стадиях Π₯ΠžΠ‘Π› ΠΏΡ€ΠΈ обострСнии ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½ΠΎ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ уровня антиоксидантных Ρ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚ΠΎΠ² (2,44 Β± 0,06 ΠΌΠΊΠ³/Π³ Hb для Π‘ΠžΠ” ΠΈ 8,30 Β± 0,15 ΠΌΠΊΠ³/Π³ Hb для ΠΊΠ°Ρ‚Π°Π»Π°Π·Ρ‹ ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с 1,56 Β± 0,02 ΠΈ 7,36 Β± 0,10 ΠΌΠΊΠ³/Π³ Hb Ρƒ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ…). На ΠΏΠΎΠ·Π΄Π½ΠΈΡ… стадиях Π₯ΠžΠ‘Π› ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ Π‘ΠžΠ” нарастаСт Π² мСньшСй стСпСни, Π° содСрТаниС ΠΊΠ°Ρ‚Π°Π»Π°Π·Ρ‹ Π΄Π°ΠΆΠ΅ пониТаСтся. Π£ срСднСтяТСлых Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π² ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ рСмиссии концСнтрация свободного оксипролина Π² ΠΊΡ€ΠΎΠ²ΠΈ составила 1,76 Β± 0,48 ΠΌΠΊΠ³/ΠΌΠ», Ρƒ тяТСлых Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… – 2,80 Β± 0,50 ΠΌΠΊΠ³/ΠΌΠ» (Ρ€ < 0,05 ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ со Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹ΠΌΠΈ). Π‘Ρ€Π΅Π΄Π½Π΅Π΅ содСрТаниС Ξ±1 -антитрипсина ΠΏΡ€ΠΈ 2-ΠΉ стадии Π₯ΠžΠ‘Π› Π² Ρ„Π°Π·Π΅ рСмиссии составило 284 Β± 47 ΠΌΠΊΠ³/ΠΌΠ», ΠΏΡ€ΠΈ 3-ΠΉ стадии – 245 Β± 18 ΠΌΠΊΠ³/ΠΌΠ», ΠΏΡ€ΠΈ обострСнии – 240 Β± 20 ΠΈ 223 Β± 15 ΠΌΠΊΠ³/ΠΌΠ» соотвСтствСнно. Π’ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅ Π²ΠΈΡ‚Π°ΠΌΠΈΠ½ΠΎΠ² Π‘ ΠΈ Π• Π² Π΄ΠΎΠ·Π°Ρ… 25 ΠΈ 5 ΠΌΠ³ Π½Π° ΠΊΠ³ массы Ρ‚Π΅Π»Π° соотвСтствСнно Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡƒΡŽ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ обострСния Π₯ΠžΠ‘Π› ΠΏΡ€ΠΈΠ²ΠΎΠ΄ΠΈΠ»ΠΎ ΠΊ ΡƒΠΊΠΎΡ€ΠΎΡ‡Π΅Π½ΠΈΡŽ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° обострСния, ΡƒΠ»ΡƒΡ‡ΡˆΠ΅Π½ΠΈΡŽ клиничСского состояния ΠΈ вСнтиляционной Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ Π»Π΅Π³ΠΊΠΈΡ…, Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠΈ АОА, сниТСнию интСнсивности ΠŸΠžΠ›. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±Ρ€Π°Π·ΠΎΠΌ, Π₯ΠžΠ‘Π› сопровоТдаСтся Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠ΅ΠΉ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΡ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½Ρ‹Ρ… процСссов, ΡΡ‚Π΅ΠΏΠ΅Π½ΡŒ ΠΊΠΎΡ‚ΠΎΡ€ΠΎΠΉ зависит ΠΎΡ‚ стадии ΠΈ Ρ„Π°Π·Ρ‹ заболСвания. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚ Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Ρ‚ΡŒ Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅ Π²ΠΈΡ‚Π°ΠΌΠΈΠ½ΠΎΠ²-антиоксидантов Π² ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΡƒ лСчСния Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π₯ΠžΠ‘Π›
    • …
    corecore